OXE 103

Drug Profile

OXE 103

Alternative Names: OXE-103

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Oxeia Biopharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries

Most Recent Events

  • 14 Dec 2016 Oxeia Biopharmaceuticals plans clinical studies for Brain injuries in USA
  • 21 Jan 2016 Preclinical trials in Brain injuries in USA (unspecified route) before January 2016
  • 21 Jan 2016 Oxeia Biopharmaceuticals in-licenses OXE 103 from University of California, San Diego
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top